@article{407d4efc52394a4aaff81e41e4c93a81,
title = "STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trial",
abstract = "The JAK/STAT3 signaling pathway may be aberrantly activated and have various and conflicting roles in breast cancer. The current study explored prognostic implications of activated STAT3 in human epidermal growth factor receptor 2 (HER2)-positive primary breast cancers in the context of a large prospective study (ALTTO). Activated STAT3 was determined by immunohistochemical analysis of STAT3 phosphorylation (Y705) performed on the primary tumors. This analysis evaluated whether patients with activated STAT3 had disease-free survival (DFS) and overall survival (OS) different from patients without activated STAT3. A total of 5694 patients out of the 8381 patients enrolled in ALTTO were included in this analysis (67.9%), and 2634 of them (46%) had evidence of STAT3 activation (minimum tumor Allred score ≥2). The median follow-up was 6.93 years (6.85-6.97 years), at the end of which 1035 (18.18%) and 520 (9.13%) patients experienced DFS and OS events, respectively. Patients with STAT3 activation experienced improved DFS compared to those without it (multivariable hazard ratio [HR], 0.84; 95% confidence interval [CI] 0.74-0.95; P =.006). There were no group differences in OS (multivariable HR, 0.92; 95% CI 0.78-1.10; P =.37). This effect was limited to ER-positive tumors. In conclusion, these findings support the role of STAT3 activation as a marker of favorable outcome in ER-positive/HER2-positive breast cancer patients.",
keywords = "ALTTO, HER2, STAT3, breast cancer, estrogen receptor",
author = "Amir Sonnenblick and Dominique Agbor-tarh and {de Azambuja}, Evandro and Susanne Hultsch and Miguel Izquierdo and Minetta Liu and Giancarlo Pruneri and Nadia Harbeck and Martine Piccart and Alvaro Moreno-Aspita and Granit, {Roy Zvi} and Ghizlane Rouas and Ibrahim Fahoum and Christos Sotiriou",
note = "Funding Information: Amir Sonnenblick is supported by a Clinical Research Career Development Award from the Israel Cancer Research Fund grants (16‐116‐CRCDA) and from the Israeli Cancer Research Association (2017‐0140). The Parasol Center for Women's Cancer Research, The Parasol Foundation. Christos Sotiriou is supported by the Breast Research Cancer Foundation (BCRF). Funding Information: Amir Sonnenblick reports consulting or advisory role from: Eli Lilly, Pfizer, Novartis. Travel, accommodations expenses: Neopharm, Celgene, Speakers bureau: Teva, Roche, Pfizer. EdA Honoraria and/or advisory board from Roche/GNE, Novartis, SeaGen and Zodiac, Libbs; Travel grants from Roche, Novartis; Research grant to institution from Roche/GNE, Astra‐Zeneca, GSK/Novartis and Servier. Miguel Izquierdo Novartis employee and own Novartis stocks. Minetta Liu Research grant to institution: EISKI, Genetech, GRAIL, MENAKINI, MERCK, Novartis, SeaGen, Teskro. Nadia Harbeck honoraria for consulting and/or lectures from Novartis. Martine Piccart Board Member (Scientific Board): Oncolytics, Consultant (honoraria): AstraZeneca, Camel‐IDS, Crescendo Biologics, Debiopharm, Genentech, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Pfizer, Radius, Roche, Seattle Genetics. Research grants to institute: AstraZeneca, Lilly, MSD, Novartis, Pfizer, Radius, Roche‐Genentech, Servier, Synthon. Alvaro Moreno‐Aspita institutional research funding from Genentech, GSK, Daiichi, Novartis, Lilly, Sermonix. Publisher Copyright: {\textcopyright} 2020 Union for International Cancer Control",
year = "2021",
month = mar,
day = "15",
doi = "10.1002/ijc.33385",
language = "English (US)",
volume = "148",
pages = "1529--1535",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",
}